Overview: Aspergillus Galactomannan BAL TestIntroduction: The Aspergillus Galactomannan BAL Test detects Aspergillus antigen in lung fluid to diagnose fungal infections, causing cough or breathing difficulty. Aligned with 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in mycology for patients with suspected fungal infections.
Other Names: Galactomannan BAL Assay, Aspergillus Antigen Test.
FDA Status: FDA-cleared diagnostic test, meeting mycology standards for diagnostic accuracy.
Historical Milestone: Galactomannan testing began in the 1990s with fungal research. BAL-based immunoassays emerged in the 2000s, improving sensitivity for invasive aspergillosis.
Purpose: Diagnoses fungal infections, guides antifungal treatment, and monitors Aspergillus antigens in patients with cough or breathing difficulty.
Test Parameters: 1. Aspergillus Galactomannan
Pretest Condition: No fasting required. Collect bronchoalveolar lavage (BAL) during bronchoscopy. Report symptoms like cough or breathing difficulty, and list medications.
Specimen: 5-10 mL bronchoalveolar lavage (sterile container). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document cough, breathing difficulty, or history of fungal infections. Include current medications, especially antifungals or immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antifungal therapy.
Procedural Considerations: Uses an immunoassay to detect Aspergillus galactomannan in BAL fluid. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Contamination or improper collection can affect results. Early infections may yield false negatives.
Clinical Significance: Positive galactomannan confirms invasive aspergillosis, prompting antifungal treatment. Negative results may require further testing.
Specialist Consultation: Consult an infectious disease specialist or pulmonologist for result interpretation.
Additional Supporting Tests: Fungal culture, chest CT, or serum galactomannan to confirm aspergillosis.
Test Limitations: False positives may occur with other fungi. Results require clinical correlation.
References: IDSA Fungal Guidelines, 2023; Clinical Infectious Diseases, Pappas PG, 2022.
